A-Alpha Bio has developed a proprietary synthetic biology platform, called AlphaSeq, that enables screening against thousands of targets in a single experimental step. An all-at-once approach saves time, reduces cost, and improves success rates.
Abacus Bioscience is focused on developing novel and game changing immunotherapies for treating chronic infectious diseases and cancers. Abacus is developing a broad-based platform that can plug-and-play with multiple cancer or viral antigens.
AbSci has developed a proprietary engineered E. coli expression system, SoluPro™ that will allow for an easily optimizable and scalable production of soluble recombinant proteins. Our game-changing core technology allows proteins (including antibodies and enzymes) to be produced at a fraction of their current cost, without any corresponding loss in performance characteristics. In addition, use of the versatile SoluPro™ platform accelerates the R&D process by enabling rapid access to soluble protein for screening purposes. These therapeutic proteins and antibodies are used in cancer and hormone therapies, as well as autoimmune and blood disorder therapies.
Accelerator Life Science Partners is a vehicle for disciplined and efficient investment in and management of emerging biotechnology opportunities. The company identifies, evaluates, finances and manages groundbreaking emerging life sciences opportunities.
Acylin is the first biotechnology company focused on developing inhibitors of cellular acylation, an enzymatic mechanism fundamental to the molecular pathology of cancer, metabolic disease and neurodegeneration.
Acquired in 2014.
Breaking drug resistance in cancer through the development of a new class of therapies that target key drivers of ongoing DNA mutation and tumor evolution.
Arzeda has the world-leading computational enzyme design technology and is changing the way people think about biocatalysis. Arzeda’s team brings more than 20 years of combined experience in the field of computational and experimental protein engineering.
Bellwether Bio is a privately-held Seattle-based startup developing novel cell-free DNA-based diagnostic technologies.
EpiThany is dedicated to the advancement of innovative therapies that can improve the lives of cancer patients. Our focus is on developing tumor vaccines that drive Th1 (tumor-eradicating) immune responses without stimulating competitive Th2 (tumor-tolerant) responses.
We're Building Something Exciting. Check Back Soon.
Hyperion Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.
Acquired by Horizon Pharma in March 2015.
Icosavax is unlocking a whole class of challenging vaccine targets to improve human health. By utilizing computationally designed proteins that self-assemble into virus-like particles (VLPs), we are able to readily manufacture VLPs displaying complex antigens to target significant unmet medical needs. Our first vaccine candidate, IVX-121, is being developed to protect older adults from respiratory syncytial virus (RSV) disease.
LUPA001: An Oral, Phase 2-Ready Biomimetic Drug for Acute and Chronic Inflammatory Diseases.
Neoleukin Therapeutics uses advanced computational methods to build entirely new – de novo – therapeutic proteins to treat serious immunological disorders, including cancer and autoimmunity.
Nexgenia’s smart, magnetic nano-particles significantly improve both speed and binding sensitivity for Diagnostic and Life Science applications.
Nohla Therapeutics is the world leader in development of ex vivo expanded universal donor cellular therapies, available on demand for treatment of life threatening diseases.
Phase Genomics' mission is to help scientists make breakthrough discoveries by providing the most complete, accurate, detailed genomes and metagenomes available from any technology.
Phytelligence has a portfolio of proprietary technologies to grow new and improved food crops faster and more reliably.
Resolve Therapeutics is pioneering a novel approach to the treatment of Systemic Lupus Erythematosus (SLE), a potentially life-threatening autoimmune disease that affects some 1.5 million people in the United States and over 5 million patients worldwide.
Rodeo Therapeutics is a preclinical-stage biotech company focused on first in class small molecule modulators of prostaglandin biology for enhancing tissue repair and regeneration.
Engineered Cells As Medicines: Repairing and controlling genes in cells or replacing missing or damaged cells can solve the underlying cause of many diseases. These emerging capabilities will create novel medicines that meaningfully improve patient outcomes, and Sana aims to lead the way.
Targeted Growth, Inc. (TGI) is a crop biotechnology company focused on developing products with enhanced yield and improved quality for the agriculture and energy industries.
VLST Corp. is a biotechnology company that has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases. The VLST platform uses novel bioinformatics and state-of-the-art proteomics to identify viral genes whose protein products function as immunomodulatory agents.
An elemental approach to better batteries: Group14 uses its unique high performance carbon engineering abilities to create cohesive silicon-carbon nanocomposites that dramatically outperform traditional carbon coated silicons. Our carbon makes any silicon work much better and when combined with our novel, low-cost nano-silicon, Group14 delivers a value proposition better than graphite.
Membrion has developed breakthrough Molecular Self Assembly (MSA) technology that uses readily available, non-toxic and low-cost materials to produce advanced ceramic ion exchange membranes which perform better and cost significantly less than today’s ceramic and polymer options. Membrion is currently deploying this versatile technology to the rapidly growing desalination market, helping to address the global water crisis.
Modumetal™ is a revolutionary nanolaminated alloy that is stronger and lighter than steel and will replace conventional metals and composites in many applications, starting with military armor, and eventually in cars, planes, buildings, and other transportation and construction sectors.
Based in Bothell, Washington, Aqueduct Critical Care was founded in October of 2013 by a group of seasoned medical device entrepreneurs led by Tom Clement, President and CEO. The company was founded to develop and commercialize technology invented at the nearby University of Washington.
Developing advanced body worn sensing and computing technologies for diagnostic testing in cardiology, respiratory and other complex disease states.
Electronic medical records don't allow visibility into outcomes across patients, and manual analyses are too slow and expensive. So, clinicians' outcomes questions go unanswered, and clinical leaders are left to manage clinical and workflow performance by intuition and anecdote. Using MDmetrix's ClinOps Control Center and AI-driven analytics, clinicians leverage real world evidence to understand outcomes, compare approaches, improve care, and monitor results--across not only patients but also teams, providers, procedures, medications, techniques, devices, and facilities.
The HIPPA Compliance Platform: Protect your organization and your patients' information. With Medcurity, you can build or complement your HIPAA Privacy and Security program with the most intuitive tools and helpful guidance available.
Since 2007, TransformativeMed has built a reputation as a worldwide leader in Cerner EMR integration and innovation, leveraging the MPages development toolkit. Our innovative solutions have enabled more than 40 hospitals to maximize the value of their EMR investment. With Smart Health Apps from TransformativeMed, hospitals can focus on what matters most: patients, providers, and outcomes.
Uptake Medical is developing a novel, minimally invasive lung volume reduction technology for patients suffering from emphysema and other types of chronic obstructive pulmonary diseases (COPD).
Acquired by Broncus Holding Company in August 2016.
We are a leading provider of GLP/GCP compliant accelerator mass spectrometry (AMS) services to the global pharmaceutical and life science industries. Our customers use AMS services to overcome challenges they face in drug development, including assessment of pharmacokinetics, metabolism and mass balance.
Rapid, non-destructive slide-free 3D pathology using a unique, proprietary open-top light-sheet microscope. The unique design enables high-throughput 3D microscopy of large and/or multiple tissue specimens.
Olis Robotics is a software product company specializing in remote control of any robotic system through Olis CoreOS software platform.
Through the CoreOS platform, Olis is able to provide market specific robot solutions that leverage Olis' proprietary machine perception and machine learning technologies. The goal of Olis' technology is to provide supervised autonomy of industrial robots to drive higher levels of operational efficiency, deliver more robust safety measures and integration of digital management frameworks of the future.
World's first receiver that combines the extreme bandwidth of direct sampling (2GHz instantaneous Nyquist bandwidth) with unprecedented high dynamic range
WiBotic provides the most reliable wireless power and battery intelligence solutions to charge your aerial, mobile and aquatic robot systems.
SNUPI Technologies is a sensor and services company focused on home safety, security, and loss prevention. Our customers use our devices, in connection with our monitoring service, to discover and alert themselves when a hazardous event occurs in their home. SNUPI (Sensor Network Utilizing Powerline Infrastructure) technology is an ultra-low-power, general-purpose wireless sensing platform that is easily used and maintained by leveraging the existing electrical wiring as a whole home antenna.
WallyHome technology acquired by Sears Holdings Corp. in October 2015.
appAttach is an online marketplace that connects PC, tablet and smartphone providers with app developers, enabling them to easily find, transact and manage preload deals.
Decide's e-commerce service finds the lowest prices for a vast range of consumer electronics and offers predictions on new model releases and future price changes.
Seattle-based C-SATS, Inc. is a venture-backed healthcare technology company on a mission to empower the nation's 16 million healthcare workers and institutions to assess and improve their performance continuously, accurately and objectively. Developed at the University of Washington, our scalable software utilizes a unique combination of distributed experts and extra-institutional reviewers to assess technical performance with accuracy equivalent to gold standards. It's Crowd-Sourced Assessment of Technical Skills...or C-SATS.
Protemo provides specialized services to the wireless industry.
Skytap is the leading provider of cloud-based virtual labs that deliver 100% self-service provisioning of complex IT environments without any architectural changes.
Washington Research Foundation values diversity. We're committed to diversity, equity and inclusion in our staff, our board of directors, and the researchers, entrepreneurs and organizations we fund. We encourage people of color, women and other underserved communities to apply for our employment, grant-making and investment opportunities.
© 2020 Washington Research Foundation, Seattle WA (206) 336-5600